Egypts bone diseases drug market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

The International Osteoporosis Foundation reported that osteoporosis is a serious disease in the Middle East. These diseases cause the bones to weaken, and they may break easily, become brittle or even develop cancer and infections. They are generally caused by poor nutrition, genetics, or problems with the rates of bone growth and rebuilding. Osteoporosis, Pagets disease of bones, rickets are some of the common types of bone diseases.

Theprevalenceof osteoporosis is relatively high amongst theEgyptianpopulation and is associated with a wide range of risk factors and medical conditions. Reports show that 53.9% of postmenopausal women have osteopenia while 28.4% have osteoporosis. 21.9% of males aged 20-89 have osteoporosis.



Market Drivers

The prevalence of osteoporosis in Egypt has been rising. In rural areas of Upper Egypt, the prevalence of osteoporosis in postmenopausal women was even higher reaching up to 47.8%. Such high prevalence highlights the magnitude of the problem in terms of public health and will lead the market for bone disease treatment in the country to grow in the forecast period.

The two fastest-growing age groups in the country are the elderly (65+) and the near-elderly (60-64), whose numbers will increase by 2.8 and 2.3 times, respectively, by 2050, relative to what they are in 2020 and this is the age bracket most affected by bone diseases. Despite ample sunshine, the Middle East registers the highest rates of rickets worldwide due to the scorching heat that keeps people indoors. This rise in the geriatric population and living conditions will increase the demand for the bone disease treatment market in the forecast period.

However, osteoporosis and other bone disease are not a national health priority in Egypt and even though guidelines have been developed, it is not endorsed by the government of the country. There is no reimbursement policy for therapy and treatments due to which people must pay. These factors act as constraints in the market growth for the disease.